Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults
- Written by PR Newswire
NANJING, China, April 14, 2023 /PRNewswire/ -- On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-7101A met the primary endpoint with excellent...